ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: A study by the GIMEMA working party on chronic myeloid leukemia

Journal of Clinical Oncology

Volumn 23, Issue 18, 2005, Pages 4100-4109

  Soverini, Simona ^a   Martinelli, Giovanni ^a   Rosti, Gianantonio ^a   Bassi, Simona ^a   Amabile, Marilina ^a   Poerio, Angela ^a   Giannini, Barbara ^a   Trabacchi, Elena ^a   Castagnetti, Fausto ^a   Testoni, Nicoletta ^a   Luatti, Simona ^a   De Vivo, Antonio ^a   Cilloni, Daniela ^a   Izzo, Barbara ^a   Fava, Milena ^a   Abruzzese, Elisabetta ^a   Alberti, Daniele ^a   Pane, Fabrizio ^a   Saglio, Giuseppe ^a   Baccarani, Michele ^a  

^a UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ABELSON KINASE; BCR ABL PROTEIN; IMATINIB; ANTINEOPLASTIC AGENT; PIPERAZINE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ADULT; AGED; ARTICLE; BONE MARROW; CANCER PATIENT; CANCER SURVIVAL; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOGENETICS; DENATURING HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; DISEASE COURSE; DRUG WITHDRAWAL; FEMALE; GENE FREQUENCY; GENE MUTATION; GENETIC SCREENING; HUMAN; MALE; MISSENSE MUTATION; MULTICENTER STUDY; POINT MUTATION; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; BLAST CELL CRISIS; CHI SQUARE DISTRIBUTION; CHROMOSOME ANALYSIS; DRUG RESISTANCE; GENETICS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; METHODOLOGY; MIDDLE AGED; MYELOID LEUKEMIA; NONPARAMETRIC TEST; NUCLEOTIDE SEQUENCE; ONCOGENE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SURVIVAL;

ADULT; AGED; ANTINEOPLASTIC AGENTS; BLAST CRISIS; CHI-SQUARE DISTRIBUTION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOGENETIC ANALYSIS; DISEASE PROGRESSION; DNA MUTATIONAL ANALYSIS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENES, ABL; HUMANS; LEUKEMIA, MYELOID, CHRONIC-PHASE; MALE; MIDDLE AGED; PIPERAZINES; POINT MUTATION; PROGNOSIS; PYRIMIDINES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STATISTICS, NONPARAMETRIC; SURVIVAL ANALYSIS;

EID: 23044458596     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.05.531     Document Type: Article

References (39)

1. Druker BJ, Talpaz M, Resta DJ, et al: Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 344:1031-1037, 2001
2. Kantarjian H, Sawyers C, Hochhaus A, et al: Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346:645-652, 2002
3. Talpaz M, Silver RT, Druker BJ, et al: Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: Results of a phase 2 study. Blood 99:1928-1937, 2002
4. Mauro MJ, O'Dwyer M, Heinrich MC, et al: STI571: A paradigm for cancer therapeutics. J Clin Oncol 20:325-334, 2002
5. Gorre ME, Mohammed M, Ellwood K, et al: Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293:876-880, 2001
6. Branford S, Rudzki Z, Walsh S, et al: High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance. Blood 99:3472-3475, 2002
7. Roumiantsev S, Shah NP, Gorre ME, et al: Clinical resistance to the kinase inhibitor STI-571 in chronic myeloid leukemia by mutation of Tyr-253 in the Abl kinase domain P-loop. Proc Natl Acad Sci U S A 99:10700-10705, 2002
8. von Bubnoff N, Schneller F, Peschel C, et al: BCR-ABL gene mutations in relation to clinical resistance of Philadelphia-chromosome-positive leukaemia to STI571: A prospective study. Lancet 359:487-491, 2002
9. Roche-Lestienne C, Soenen-Cornu V, Grardel-Duflos N, et al: Several types of mutations of the Abl gene can be found in chronic myeloid leukemia patients resistant to STI571, and they can pre-exist to the onset of treatment. Blood 100:1014-1018, 2002
10. Shah NP, Nicoll JM, Nagar B, et al: Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor Imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell 2:117-125, 2002
11. Hofmann WK, Jones LC, Lemp NA, et al: Ph (+) acute lymphoblastic leukemia resistant to the tyrosine kinase inhibitor STI571 has a unique BCR-ABL gene mutation. Blood 99:1860-1862, 2002
12. Hochhaus A, Kreil S, Corbin AS, et al: Molecular and chromosomal mechanisms of resistance to Imatinib (STI571) therapy. Leukemia 16:2190-2196, 2002
13. Schindler T, Bornmann W, Pellicena P, et al: Structural mechanism for STI-571 inhibition of Abelson tyrosine kinase. Science 289:1938-1942, 2000
14. Nagar B, Bornmann WG, Pellicena P, et al: Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and Imatinib (STI-571). Cancer Res 62:4236-4243, 2002
15. Druker BJ, Tamura S, Buchdunger E, et al: Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med 2:561-566, 1996
16. Gambacorti-Passerini C, le Coutre P, Mologni L, et al: Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis. Blood Cells Mol Dis 23:380-394, 1997
17. Deininger MW, Goldman JM, Lydon N, et al: The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells. Blood 90:3691-3698, 1997
18. Bohmer FD, Karagyozov L, Uecker A, et al: A single amino acid exchange inverts susceptibility of related receptor tyrosine kinases for the ATP site inhibitor STI-571. J Biol Chem 278: 5148-5155, 2003
19. Corbin AS, Buchdunger E, Pascal F, et al: Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571. J Biol Chem 277:32214-32219, 2002
20. Branford S, Rudzki Z, Walsh S, et al: Detection of BCR-ABL mutations in patients with CML treated with Imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood 102:276-283, 2003
21. Soverini S, Martinelli G, Amabile M, et al: A denaturing-high performance liquid chromatography (D-HPLC)-based assay for detection of ABL mutations in chronic myeloid leukemia patients resistant to Imatinib. Clin Chem 50:1205-1213, 2004
22. Rosti G, Martinelli G, Bassi S, et al: Molecular response to Imatinib in late chronic phase chronic myeloid leukemia. Blood 103:2284-2290, 2004
23. Martinelli G, Ottaviani E, Testoni N, et al: Long-term disease-free acute myeloblastic leukemia with inv(16) is associated with PCR undetectable CBF-beta/MYH11 transcript. Haematologica 85:552-555, 2000
24. Kreuzer KA, Le Coutre P, Landt O, et al: Preexistence and evolution of imatinib mesylate-resistant clones in chronic myelogenous leukemia detected by a PNA-based PCR clamping technique. Ann Hematol 82:284-289, 2003
25. + acute lymphoblastic leukemia. Blood 102:659-661, 2003
26. Xiao W, Oefner P: Denaturing high-performance liquid chromatography: A review. Hum Mutat 17:439-474, 2001
27. Wolford JK, Blunt D, Ballecer K, et al: High-throughput SNP detection by using DNA pooling and denaturing high performance liquid chromatography (DHPLC). Hum Genet 107:483-487, 2000
28. Baumer A, Wiedermann U, Hergersberg M, et al: A novel MSP/DHPLC method for the investigation of the methylation status of imprinted genes enables the molecular detection of low cell mosaicisms. Hum Mutat 17:423-430, 2001
29. Emmerson P, Maynard J, Jones S, et al: Characterizing mutations in samples with low-level mosaicism by collection and analysis of DHPLC fractionated heteroduplexes. Hum Mutat 21:112-115, 2003
30. Deininger MWN, McGreevey L, Willis S, et al: Detection of ABL kinase domain mutations with denaturing high-performance liquid chromatography. Leukemia 18:864-871, 2004
31. Shah NP, Tran C, Lee FY, et al: Overriding imatinib resistance with a novel ABL kinase inhibitor. Science 305:399-401, 2004
32. O'Hare T, Pollock R, Stoffregen EP, et al: Inhibition of wild-type and mutant Bcr-Abl by AP23464, a potent ATP-based oncogenic protein kinase inhibitor: Implications for CML. Blood 104:2532-2539, 2004
33. Giles F, Kantarjian H, Wassmann B, et al: A phase I/II study of AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, on a continuous daily dosing schedule in adult patients (pts) with imatinib-resistant advanced phase chronic myeloid leukemia (CML) or relapsed/refractory Philadelphia chromosome (Ph+) acute lymphocytic leukemia (ALL). Blood 104:10a, 2004 (abstr)
34. Talpaz M, Kantarjian HM, Shah NP, et al: Hematologic and cytogenetic responses in imatinib-resistant accelerated and blast phase chronic myeloid leukemia (CML) patients treated with the dual SRC/ABL kinase inhibitor BMS-354825: Results from a phase I dose escalation study. Blood 104:10a, 2004 (abstr)
35. Sawyers CL, Shah NP, Kantarjian HM, et al: Hematologic and cytogenetic responses in imatinib-resistant chronic phase chronic myeloid leukemia patients treated with the dual SRC/ABL kinase inhibitor BMS-354825: results from a phase I dose escalation study. Blood 104:4a, 2004 (abstr)
36. Corbin AS, Rosee PL, Stoffregen EP, et al: Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood 101:4611-4614, 2003
37. Capdeville R, Silberman S: Imatinib: A targeted clinical drug development. Semin Hematol 40:15-20, 2003
38. Allen P, Weidemann M: An activating mutation in the ATP binding site of the ABL kinase domain. J Biol Chem 271:19585-19591, 1996
39. Yamamoto M, Kurosu T, Kakihana K, et al: The two major imatinib resistance mutations E255K and T315I enhance the activity of BCR/ ABL fusion kinase. Biochem Biophys Res Commun 319:1272-1275, 2004